CoChat

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

Tanegashima, Tokiyoshi, Togashi, Yosuke, Azuma, Koichi, Kawahara, Akihiko, Ideguchi, Ko, Sugiyama, Daisuke, Kinoshita, Fumio, Akiba, Jun, Kashiwagi, Eiji, Takeuchi, Ario, Irie, Takuma, Tatsugami, Katsunori, Hoshino, Tomoaki, Eto, Masatoshi, Nishikawa, Hiroyoshi · 2019 · Clinical Cancer Research
Cited by 93

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Purpose: To evaluate the detailed immunosuppressive role(s) of PD-L2 given that its detailed role(s) remains unclear in PD-1 signal blockade therapy in animal models and humans. Experimental Design: We generated mouse cell lines harboring various status of PD-L1/PD-L2 and evaluated the tumor growth and phenotypes of tumor-infiltrated lymphocytes using several PD-1 signal blockades in animal models. In humans, the correlation between immune-related gene expression and CD274 (encoding PD-L1) or PDCD1LG2 (encoding PD-L2) was investigated using The Cancer Genome Atlas (TCGA) datasets. In addition, PD-L1 or PD-L2 expression in tumor cells and CD8+ T-cell infiltration were assessed by IHC. Results: In animal models, we showed that PD-L2 expression alone or simultaneously expressed with PD-L1 in tumor cells significantly suppressed antitumor immune responses, such as tumor antigen–specific CD8+ T cells, and was involved in the resistance to treatment with anti-PD-L1 mAb alone. This resistance was overcome by anti-PD-1 mAb or combined treatment with anti-PD-L2 mAb. In clinical settings, antitumor immune responses were significantly correlated with PD-L2 expression in the tumor microenvironment in renal cell carcinoma (RCC) and lung squamous cell carcinoma (LUSC). Conclusions: We propose that PD-L2 as well as PD-L1 play important roles in evading antitumor immunity, suggesting that PD-1/PD-L2 blockade must be considered for optimal immunotherapy in PD-L2–expressing cancers, such as RCC and LUSC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3991

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 93

Metadata

Authors
Tanegashima, T., Togashi, Y., Azuma, K., Kawahara, A., Ideguchi, K., Sugiyama, D., Kinoshita, F., Akiba, J., Kashiwagi, E., Takeuchi, A., Irie, T., Tatsugami, K., Hoshino, T., Eto, M., & Nishikawa, H.
Venue
Clinical Cancer Research
Published
2019-08-01
Volume
25
Issue
15
Pages
4808-4819
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2944181742
Cited by
93
References
20
FWCI
5.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3991
The paper
Tanegashima, T., Togashi, Y., Azuma, K., Kawahara, A., Ideguchi, K., Sugiyama, D., Kinoshita, F., Akiba, J., Kashiwagi, E., Takeuchi, A., Irie, T., Tatsugami, K., Hoshino, T., Eto, M., & Nishikawa, H. (2019). Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3991

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.